FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943944580> ?p ?o ?g. }

• W2943944580 endingPage "175883591984642" @default.
• W2943944580 startingPage "175883591984642" @default.
• W2943944580 abstract "Background: Intensive triplet chemotherapy/bevacizumab significantly increased metastatic colorectal cancer (MCRC) outcome. This phase II study investigated the safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line RAS wild-type and the prediction of individual limiting toxicity syndromes (LTS) by pharmacogenomic biomarkers. Methods: A Simon two-step design was used: p0 70%, p1 85%, power 80%, α5%, β20%; projected objective response rate (ORR) I step 14/19. FIr-C/FOx-C: 5-fluorouracil (5-FU) 12h-timed flat infusion 900 mg/m 2 d1–2, 8–9, 15–16, 22–23; irinotecan (CPT-11) 160 mg/m 2 d1 and 15, oxaliplatin 80 mg/m 2 d8 and 22; CET 400mg/m 2 then 250 mg/m 2 d1, 8, 15, 22; every 28 days. Toxicity, and individual LTS were evaluated, compared by a Chi-square test; and activity/efficacy by log-rank. 5-FU/CPT-11 pharmacogenomic biomarkers, 5-FU degradation rate (5-FUDR), single nucleotide polymorphisms (SNPs) ABCB1, CYP3A4, DYPD, UGT1A1 were evaluated in patients with LTS and at a recommended dose. Results: A total of 29 patients <75 years, with a primary/intermediate Cumulative Index Rating Scale were enrolled; the median age was 59 years; there were 7 young-elderly (yE; 24%). Recommended CPT-11/5-FU doses were 120/750 mg/m 2 . In the intent-to-treat analysis, the ORR was 58.6%. The primary endpoint was met in patients who received the planned three treatment cycles: the objective response (OR) was 14/18 (78%). At a median follow up of 18 months, progression-free survival (PFS) was 12, and overall survival (OS) was 23 months. At the recommended doses (received dose intensity >80%), grade 3–4 toxicities were: diarrhea 23%, asthenia 15%, vomiting 8%, hypertransaminasemy 8%; LTS 19 (65.5%), with 83% in yE patients. LTS prevalently multiple (ms) versus single site were 59% versus 7% ( p = 0.006). The prevalence of reduced FUDR was 56%, SNPs CYP3A4 22%, UGT1A1 71%, and of >2 positive pharmacogenomics biomarkers was 78%, prevalently reported in patients who developed gastrointestinal LTS. Conclusions: FIr-C/FOx-C is highly active and tolerable at recommended doses in non-elderly RAS wild-type MCRC patients. LTS provided an evaluation of the toxicity burden in individual patients. Reduced FUDR, CYP3A4, and UGT1A1 SNPs may predict individual LTS-ms in patients at risk of limiting gastrointestinal toxicity. Trial registration: The trial was registered at Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali (OsSC) Agenzia Italiana del Farmaco (AIFA) Numero EudraCT 2009-016793-32." @default.
• W2943944580 created "2019-05-16" @default.
• W2943944580 creator A5017669867 @default.
• W2943944580 creator A5019038297 @default.
• W2943944580 creator A5032330087 @default.
• W2943944580 creator A5035469274 @default.
• W2943944580 creator A5047578327 @default.
• W2943944580 creator A5058140083 @default.
• W2943944580 creator A5071102498 @default.
• W2943944580 creator A5082847339 @default.
• W2943944580 creator A5086176903 @default.
• W2943944580 creator A5088146814 @default.
• W2943944580 date "2019-01-01" @default.
• W2943944580 modified "2023-10-12" @default.
• W2943944580 title "Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers" @default.
• W2943944580 cites W1964358748 @default.
• W2943944580 cites W1964689750 @default.
• W2943944580 cites W1965015745 @default.
• W2943944580 cites W1974441888 @default.
• W2943944580 cites W1987707107 @default.
• W2943944580 cites W1993780950 @default.
• W2943944580 cites W1995854801 @default.
• W2943944580 cites W2005348280 @default.
• W2943944580 cites W2015132197 @default.
• W2943944580 cites W2029409133 @default.
• W2943944580 cites W2047342365 @default.
• W2943944580 cites W2063886520 @default.
• W2943944580 cites W2068473448 @default.
• W2943944580 cites W2085633477 @default.
• W2943944580 cites W2090536986 @default.
• W2943944580 cites W2108235590 @default.
• W2943944580 cites W2112570485 @default.
• W2943944580 cites W2119954911 @default.
• W2943944580 cites W2124794153 @default.
• W2943944580 cites W2129998117 @default.
• W2943944580 cites W2139248078 @default.
• W2943944580 cites W2142650716 @default.
• W2943944580 cites W2149628418 @default.
• W2943944580 cites W2149781789 @default.
• W2943944580 cites W2187668060 @default.
• W2943944580 cites W2203602330 @default.
• W2943944580 cites W2229509524 @default.
• W2943944580 cites W2284759725 @default.
• W2943944580 cites W2562739217 @default.
• W2943944580 cites W2616257794 @default.
• W2943944580 cites W4293241248 @default.
• W2943944580 doi "https://doi.org/10.1177/1758835919846421" @default.
• W2943944580 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6535746" @default.
• W2943944580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31205502" @default.
• W2943944580 hasPublicationYear "2019" @default.
• W2943944580 type Work @default.
• W2943944580 sameAs 2943944580 @default.
• W2943944580 citedByCount "7" @default.
• W2943944580 countsByYear W29439445802019 @default.
• W2943944580 countsByYear W29439445802020 @default.
• W2943944580 countsByYear W29439445802021 @default.
• W2943944580 countsByYear W29439445802022 @default.
• W2943944580 crossrefType "journal-article" @default.
• W2943944580 hasAuthorship W2943944580A5017669867 @default.
• W2943944580 hasAuthorship W2943944580A5019038297 @default.
• W2943944580 hasAuthorship W2943944580A5032330087 @default.
• W2943944580 hasAuthorship W2943944580A5035469274 @default.
• W2943944580 hasAuthorship W2943944580A5047578327 @default.
• W2943944580 hasAuthorship W2943944580A5058140083 @default.
• W2943944580 hasAuthorship W2943944580A5071102498 @default.
• W2943944580 hasAuthorship W2943944580A5082847339 @default.
• W2943944580 hasAuthorship W2943944580A5086176903 @default.
• W2943944580 hasAuthorship W2943944580A5088146814 @default.
• W2943944580 hasBestOaLocation W29439445801 @default.
• W2943944580 hasConcept C121608353 @default.
• W2943944580 hasConcept C126322002 @default.
• W2943944580 hasConcept C143998085 @default.
• W2943944580 hasConcept C203092338 @default.
• W2943944580 hasConcept C2776694085 @default.
• W2943944580 hasConcept C2777802072 @default.
• W2943944580 hasConcept C2779998722 @default.
• W2943944580 hasConcept C2780259306 @default.
• W2943944580 hasConcept C2780962732 @default.
• W2943944580 hasConcept C29730261 @default.
• W2943944580 hasConcept C526805850 @default.
• W2943944580 hasConcept C535046627 @default.
• W2943944580 hasConcept C71924100 @default.
• W2943944580 hasConcept C90924648 @default.
• W2943944580 hasConceptScore W2943944580C121608353 @default.
• W2943944580 hasConceptScore W2943944580C126322002 @default.
• W2943944580 hasConceptScore W2943944580C143998085 @default.
• W2943944580 hasConceptScore W2943944580C203092338 @default.
• W2943944580 hasConceptScore W2943944580C2776694085 @default.
• W2943944580 hasConceptScore W2943944580C2777802072 @default.
• W2943944580 hasConceptScore W2943944580C2779998722 @default.
• W2943944580 hasConceptScore W2943944580C2780259306 @default.
• W2943944580 hasConceptScore W2943944580C2780962732 @default.
• W2943944580 hasConceptScore W2943944580C29730261 @default.
• W2943944580 hasConceptScore W2943944580C526805850 @default.
• W2943944580 hasConceptScore W2943944580C535046627 @default.
• W2943944580 hasConceptScore W2943944580C71924100 @default.
• W2943944580 hasConceptScore W2943944580C90924648 @default.
• W2943944580 hasLocation W29439445801 @default.

• next